Stock KDA KDA GROUP INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials KDA Group Inc.

Equities

KDA

CA48669F1071

Biotechnology & Medical Research

Market Closed - Toronto S.E.
Other stock markets
 20:47:51 13/05/2024 BST 		5-day change 1st Jan Change
0.395 CAD +3.95% Intraday chart for KDA Group Inc. -7.06% +97.50%
03-28 KDA Group Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024 CI
03-21 KDA Group Inc. Announces an Update in the Development and Use of Its Adherize+ Platform CI

Valuation

Fiscal Period: July 2018 2019 2020 2021 2022 2023
Capitalization 1 9.874 21.69 17.76 19.18 16.3 13.6
Enterprise Value (EV) 1 28.73 35.7 34.25 30.41 36.23 12.25
P/E ratio -1.88 x -2.16 x -3.87 x 29.3 x -3.57 x 0.79 x
Yield - - - - - -
Capitalization / Revenue 0.38 x 0.94 x 0.78 x 0.79 x 0.57 x 84.4 x
EV / Revenue 1.1 x 1.55 x 1.5 x 1.25 x 1.26 x 76 x
EV / EBITDA -147 x 148 x 68.1 x 16.4 x 24.2 x -4.09 x
EV / FCF 38.2 x 6.77 x -6.36 x 6.68 x -13.8 x -2.31 x
FCF Yield 2.62% 14.8% -15.7% 15% -7.23% -43.2%
Price to Book -2.38 x -3.52 x -5.94 x 4.9 x -80.4 x 0.82 x
Nbr of stocks (in thousands) 42,931 86,761 118,421 147,541 148,141 159,966
Reference price 2 0.2300 0.2500 0.1500 0.1300 0.1100 0.0850
Announcement Date 30/11/18 28/11/19 30/11/20 29/11/21 25/11/22 28/11/23
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: July 2018 2019 2020 2021 2022 2023
Net sales 1 26.08 23.09 22.89 24.36 28.82 0.1611
EBITDA 1 -0.1951 0.2415 0.5032 1.856 1.498 -2.999
EBIT 1 -1.193 -0.1207 -0.1011 1.439 1.183 -3.309
Operating Margin -4.58% -0.52% -0.44% 5.91% 4.11% -2,053.85%
Earnings before Tax (EBT) 1 -5.71 -7.438 -5.347 0.3427 -4.646 2.473
Net income 1 -5.212 -8.516 -4.31 0.5615 -4.562 16.14
Net margin -19.98% -36.88% -18.83% 2.31% -15.83% 10,015.99%
EPS 2 -0.1222 -0.1158 -0.0387 0.004442 -0.0308 0.1083
Free Cash Flow 1 0.753 5.277 -5.388 4.555 -2.62 -5.295
FCF margin 2.89% 22.85% -23.54% 18.7% -9.09% -3,286.3%
FCF Conversion (EBITDA) - 2,184.75% - 245.41% - -
FCF Conversion (Net income) - - - 811.19% - -
Dividend per Share - - - - - -
Announcement Date 30/11/18 28/11/19 30/11/20 29/11/21 25/11/22 28/11/23
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: July 2018 2019 2020 2021 2022 2023
Net Debt 1 18.9 14 16.5 11.2 19.9 -
Net Cash position 1 - - - - - 1.34
Leverage (Debt/EBITDA) -96.63 x 58 x 32.76 x 6.05 x 13.31 x -
Free Cash Flow 1 0.75 5.28 -5.39 4.55 -2.62 -5.3
ROE (net income / shareholders' equity) 312% 167% 89% 686% -246% 7.59%
ROA (Net income/ Total Assets) -2.69% -0.37% -0.35% 4.27% 2.91% -8.19%
Assets 1 193.7 2,318 1,229 13.15 -156.9 -196.9
Book Value Per Share 2 -0.1000 -0.0700 -0.0300 0.0300 -0 0.1000
Cash Flow per Share 2 0.0200 0.0100 0.0200 0.0100 0.0200 0.0300
Capex 1 0.33 0.39 0.89 0.05 0.05 0
Capex / Sales 1.26% 1.7% 3.89% 0.2% 0.16% 2.91%
Announcement Date 30/11/18 28/11/19 30/11/20 29/11/21 25/11/22 28/11/23
1CAD in Million2CAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
KDA GROUP INC. Stock KDA Group Inc.
+97.50% 48.79M
MODERNA, INC. Stock Moderna, Inc.
+26.37% 44.96B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.01% 42.65B
LONZA GROUP AG Stock Lonza Group AG
+46.00% 41.85B
CELLTRION, INC. Stock Celltrion, Inc.
-5.31% 29.04B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.34% 26.08B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.69% 19.03B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+6.23% 12.75B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.99% 12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.38% 11.75B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. KDA Stock
  4. Financials KDA Group Inc.